slc6a3-cre Search Results


dat cre  (Jackson Laboratory)
86
Jackson Laboratory dat cre
( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds <t>in</t> <t>DAT-Cre</t> mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
Dat Cre, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc6a3-cre/cre+dat+mice/bio_rxiv__64898__2026__03__27__714928-145-11-13
Average 86 stars, based on 1 article reviews
dat cre - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
heterozygous b6 sjl slc6a3 tm1 1 cre bkmn j mice  (Jackson Laboratory)
86
Jackson Laboratory heterozygous b6 sjl slc6a3 tm1 1 cre bkmn j mice
( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds <t>in</t> <t>DAT-Cre</t> mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
Heterozygous B6 Sjl Slc6a3 Tm1 1 Cre Bkmn J Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc6a3-cre/heterozygous+mice/pmc08528033-322-26-37
Average 86 stars, based on 1 article reviews
heterozygous b6 sjl slc6a3 tm1 1 cre bkmn j mice - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
dat ires cre  (Jackson Laboratory)
86
Jackson Laboratory dat ires cre
( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds <t>in</t> <t>DAT-Cre</t> mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
Dat Ires Cre, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc6a3-cre/cre+vglut2/pmc13045366-23-26-35
Average 86 stars, based on 1 article reviews
dat ires cre - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
dat irescre  (Jackson Laboratory)
86
Jackson Laboratory dat irescre
a Left , Illustration showing TS injection site for AAV-DIO-TetTx-eGFP or AAV-DIO-eGFP. Right , Representative brightfield and fluorescence images showing the extent of viral infection in TS. b Behavioral paradigm used for auditory threat conditioning. c Graph showing average % freeze during auditory tones for the habituation phase (before dotted line) and conditioning phase (after dotted line). Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars are ± SEM. d Graph showing the average % freeze during auditory tones for the retrieval phase. Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars ± SEM. e Average % freeze during habituation, conditioning, and retrieval phases for control (eGFP, N = 8, gray ) and treated (TetTx, N = 8, red ) mice. Two-way ANOVA showed significant treatment ( p = 0.0018), phase ( p = 0.0027), and phase-treatment interaction ( p = 0.0225). Sidak’s post-hoc test revealed a significant difference between groups during conditioning ( p = 0.04) and retrieval ( p = 0.0002). Box whiskers represent 25–75% percentiles, solid squares are the mean value, and horizontal box lines represent medians. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. <t>DAT</t> <t>IRESCre</t> <t>(B6.SJL-Slc6a3</t> <t>tm1.1(cre)Bkmn</t> /J) mice were used at 3 months of age, and each experimental group was composed of 50% male and 50% male. Created in BioRender. Sansalone, L. (2025) https://BioRender.com/4cs5d9o , https://BioRender.com/021exyd , https://BioRender.com/d9tvdx3 . Source data have been uploaded on Zenodo (10.5281/zenodo.15486331, 2025).
Dat Irescre, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc6a3-cre/dat+irescre/pmc12462460-230-5-10
Average 86 stars, based on 1 article reviews
dat irescre - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
b6 sjl slc6a3 tm1 1 cre bkmn j  (Jackson Laboratory)
86
Jackson Laboratory b6 sjl slc6a3 tm1 1 cre bkmn j
a Left , Illustration showing TS injection site for AAV-DIO-TetTx-eGFP or AAV-DIO-eGFP. Right , Representative brightfield and fluorescence images showing the extent of viral infection in TS. b Behavioral paradigm used for auditory threat conditioning. c Graph showing average % freeze during auditory tones for the habituation phase (before dotted line) and conditioning phase (after dotted line). Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars are ± SEM. d Graph showing the average % freeze during auditory tones for the retrieval phase. Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars ± SEM. e Average % freeze during habituation, conditioning, and retrieval phases for control (eGFP, N = 8, gray ) and treated (TetTx, N = 8, red ) mice. Two-way ANOVA showed significant treatment ( p = 0.0018), phase ( p = 0.0027), and phase-treatment interaction ( p = 0.0225). Sidak’s post-hoc test revealed a significant difference between groups during conditioning ( p = 0.04) and retrieval ( p = 0.0002). Box whiskers represent 25–75% percentiles, solid squares are the mean value, and horizontal box lines represent medians. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. <t>DAT</t> <t>IRESCre</t> <t>(B6.SJL-Slc6a3</t> <t>tm1.1(cre)Bkmn</t> /J) mice were used at 3 months of age, and each experimental group was composed of 50% male and 50% male. Created in BioRender. Sansalone, L. (2025) https://BioRender.com/4cs5d9o , https://BioRender.com/021exyd , https://BioRender.com/d9tvdx3 . Source data have been uploaded on Zenodo (10.5281/zenodo.15486331, 2025).
B6 Sjl Slc6a3 Tm1 1 Cre Bkmn J, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc6a3-cre/b6+boyj+pepcb+ptprca+sjl/pmc09789200-770-0-8
Average 86 stars, based on 1 article reviews
b6 sjl slc6a3 tm1 1 cre bkmn j - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

Journal: bioRxiv

Article Title: Vagal dopaminergic afferents link interoception to trigeminal pain modulation

doi: 10.64898/2026.03.27.714928

Figure Lengend Snippet: ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

Article Snippet: Adult male and female mice (8–12 weeks old) were used, including DAT-Cre (Slc6a3-Cre; The Jackson Laboratory, stock #006660) , TH-Cre (The Jackson Laboratory, stock #025614) , TrkC-Cre (Ntrk3-Cre; The Jackson Laboratory, stock #030291) , MrgD-Cre (Mrgprd-Cre; The Jackson Laboratory, stock #031286) , CGRP-Cre (from Pao-Tien Chuang, University of California, San Francisco) , and wild-type C57BL/6J (The Jackson Laboratory, stock #000664) ( ).

Techniques: Injection, Activity Assay, Conditioned Place Preference, Fluorescence, Expressing, Infection, Control

( A ) CPP experimental timeline. On day 9 (pre-test), mice freely explored both chambers. Days 10-12: Morning saline and afternoon C21 conditioning sessions (6 h apart). Day 13: Test phase with free access to both chambers. ( B ) CPP scores (Δ time in C21-paired chamber) in different Cre lines. ( C ) Representative tracking traces of mice during the pre-test and test sessions in the CPP chamber. ( D ) Comparison of WT and DAT-Cre mice with or without C21 treatment to determine if the CPP effect was specific to DAT-Cre mice. Data are median ± IQR; **p < 0.01, ***p < 0.001 (Wilcoxon signed-rank test vs 0 and Kruskal–Wallis with Dunn’s post hoc). ( E ) Representative tracking traces illustrating changes in chamber preference from the pre-test to the test session in the CPP chamber.

Journal: bioRxiv

Article Title: Vagal dopaminergic afferents link interoception to trigeminal pain modulation

doi: 10.64898/2026.03.27.714928

Figure Lengend Snippet: ( A ) CPP experimental timeline. On day 9 (pre-test), mice freely explored both chambers. Days 10-12: Morning saline and afternoon C21 conditioning sessions (6 h apart). Day 13: Test phase with free access to both chambers. ( B ) CPP scores (Δ time in C21-paired chamber) in different Cre lines. ( C ) Representative tracking traces of mice during the pre-test and test sessions in the CPP chamber. ( D ) Comparison of WT and DAT-Cre mice with or without C21 treatment to determine if the CPP effect was specific to DAT-Cre mice. Data are median ± IQR; **p < 0.01, ***p < 0.001 (Wilcoxon signed-rank test vs 0 and Kruskal–Wallis with Dunn’s post hoc). ( E ) Representative tracking traces illustrating changes in chamber preference from the pre-test to the test session in the CPP chamber.

Article Snippet: Adult male and female mice (8–12 weeks old) were used, including DAT-Cre (Slc6a3-Cre; The Jackson Laboratory, stock #006660) , TH-Cre (The Jackson Laboratory, stock #025614) , TrkC-Cre (Ntrk3-Cre; The Jackson Laboratory, stock #030291) , MrgD-Cre (Mrgprd-Cre; The Jackson Laboratory, stock #031286) , CGRP-Cre (from Pao-Tien Chuang, University of California, San Francisco) , and wild-type C57BL/6J (The Jackson Laboratory, stock #000664) ( ).

Techniques: Saline, Comparison

( A ) Schematic illustration of the experimental timeline for in vivo Pirt-GCaMP3 Ca2+ imaging. ( B ) Representative calcium activity maps of trigeminal ganglion (TG) neurons expressing GCaMP3 in DAT-Cre; GCaMP3 mice after FMO with or without C21 treatment. V1–V3 indicate the ophthalmic, maxillary, and mandibular branches of the TG. White arrowheads denote spontaneously active neurons. ( C ) Heat maps showing calcium activity of individual TG neurons over time. ( D ) Quantification of the total number of spontaneously active neurons grouped by soma size (small, medium, large). ( E to J ) Quantification of TG neurons activated by different V3 stimuli: (E) 0.4 g filament, (F) 2 g filament, (G) small brush, (H) cold (4°C), (I) heat (50°C), and (J) capsaicin. Data are presented as mean ± s.e.m. (n = 5 mice per group). *p < 0.05, **p < 0.01, ****p < 0.0001 (Two-way ANOVA followed by Tukey’s multiple-comparisons test).

Journal: bioRxiv

Article Title: Vagal dopaminergic afferents link interoception to trigeminal pain modulation

doi: 10.64898/2026.03.27.714928

Figure Lengend Snippet: ( A ) Schematic illustration of the experimental timeline for in vivo Pirt-GCaMP3 Ca2+ imaging. ( B ) Representative calcium activity maps of trigeminal ganglion (TG) neurons expressing GCaMP3 in DAT-Cre; GCaMP3 mice after FMO with or without C21 treatment. V1–V3 indicate the ophthalmic, maxillary, and mandibular branches of the TG. White arrowheads denote spontaneously active neurons. ( C ) Heat maps showing calcium activity of individual TG neurons over time. ( D ) Quantification of the total number of spontaneously active neurons grouped by soma size (small, medium, large). ( E to J ) Quantification of TG neurons activated by different V3 stimuli: (E) 0.4 g filament, (F) 2 g filament, (G) small brush, (H) cold (4°C), (I) heat (50°C), and (J) capsaicin. Data are presented as mean ± s.e.m. (n = 5 mice per group). *p < 0.05, **p < 0.01, ****p < 0.0001 (Two-way ANOVA followed by Tukey’s multiple-comparisons test).

Article Snippet: Adult male and female mice (8–12 weeks old) were used, including DAT-Cre (Slc6a3-Cre; The Jackson Laboratory, stock #006660) , TH-Cre (The Jackson Laboratory, stock #025614) , TrkC-Cre (Ntrk3-Cre; The Jackson Laboratory, stock #030291) , MrgD-Cre (Mrgprd-Cre; The Jackson Laboratory, stock #031286) , CGRP-Cre (from Pao-Tien Chuang, University of California, San Francisco) , and wild-type C57BL/6J (The Jackson Laboratory, stock #000664) ( ).

Techniques: In Vivo, Imaging, Activity Assay, Expressing

a Left , Illustration showing TS injection site for AAV-DIO-TetTx-eGFP or AAV-DIO-eGFP. Right , Representative brightfield and fluorescence images showing the extent of viral infection in TS. b Behavioral paradigm used for auditory threat conditioning. c Graph showing average % freeze during auditory tones for the habituation phase (before dotted line) and conditioning phase (after dotted line). Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars are ± SEM. d Graph showing the average % freeze during auditory tones for the retrieval phase. Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars ± SEM. e Average % freeze during habituation, conditioning, and retrieval phases for control (eGFP, N = 8, gray ) and treated (TetTx, N = 8, red ) mice. Two-way ANOVA showed significant treatment ( p = 0.0018), phase ( p = 0.0027), and phase-treatment interaction ( p = 0.0225). Sidak’s post-hoc test revealed a significant difference between groups during conditioning ( p = 0.04) and retrieval ( p = 0.0002). Box whiskers represent 25–75% percentiles, solid squares are the mean value, and horizontal box lines represent medians. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. DAT IRESCre (B6.SJL-Slc6a3 tm1.1(cre)Bkmn /J) mice were used at 3 months of age, and each experimental group was composed of 50% male and 50% male. Created in BioRender. Sansalone, L. (2025) https://BioRender.com/4cs5d9o , https://BioRender.com/021exyd , https://BioRender.com/d9tvdx3 . Source data have been uploaded on Zenodo (10.5281/zenodo.15486331, 2025).

Journal: Nature Communications

Article Title: Corticonigral projections recruit substantia nigra pars lateralis dopaminergic neurons for auditory threat memories

doi: 10.1038/s41467-025-63132-8

Figure Lengend Snippet: a Left , Illustration showing TS injection site for AAV-DIO-TetTx-eGFP or AAV-DIO-eGFP. Right , Representative brightfield and fluorescence images showing the extent of viral infection in TS. b Behavioral paradigm used for auditory threat conditioning. c Graph showing average % freeze during auditory tones for the habituation phase (before dotted line) and conditioning phase (after dotted line). Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars are ± SEM. d Graph showing the average % freeze during auditory tones for the retrieval phase. Each squared symbol represents the average for a 30 s pure tone ( N = 8 for each group). Whisker bars ± SEM. e Average % freeze during habituation, conditioning, and retrieval phases for control (eGFP, N = 8, gray ) and treated (TetTx, N = 8, red ) mice. Two-way ANOVA showed significant treatment ( p = 0.0018), phase ( p = 0.0027), and phase-treatment interaction ( p = 0.0225). Sidak’s post-hoc test revealed a significant difference between groups during conditioning ( p = 0.04) and retrieval ( p = 0.0002). Box whiskers represent 25–75% percentiles, solid squares are the mean value, and horizontal box lines represent medians. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. DAT IRESCre (B6.SJL-Slc6a3 tm1.1(cre)Bkmn /J) mice were used at 3 months of age, and each experimental group was composed of 50% male and 50% male. Created in BioRender. Sansalone, L. (2025) https://BioRender.com/4cs5d9o , https://BioRender.com/021exyd , https://BioRender.com/d9tvdx3 . Source data have been uploaded on Zenodo (10.5281/zenodo.15486331, 2025).

Article Snippet: The following strains were used: DAT IRESCre (B6.SJL-Slc6a3 tm1.1(cre)Bkmn /J), The Jackson Laboratory, Strain #: 006660; VGluT2 IRESCre (Slc17a6 tm2(cre)Lowl /J), The Jackson Laboratory, Strain #: 016963; Calb1- IRES2-Cre-D (B6;129S-Calb1 tm2.1(cre)Hze /J), The Jackson Laboratory, Strain #: 028532); DAT-Flp (Slc6a3 em1(flpo)Hbat /J) , The Jackson Laboratory, Strain #: 035436; Ai65(RCFL-tdT)-D (B6.129S-Gt(ROSA)26Sor tm65(CAG-tdTomato)Hze /J, The Jackson Laboratory, Strain #: 021875); Ai9(RCL-tdT) (B6.129S6-Gt(ROSA)26Sor tm9(CAG-tdTomato)Hze /J, The Jackson Laboratory, Strain #: 007905; C57BL/6 (C57BL/6NCrl, Charles River Laboratories, Strain #: 027); Tyrosine hydroxylase-GFP (Th-GFP; C57BL/6 background 38 ).

Techniques: Injection, Fluorescence, Infection, Whisker Assay, Control